Brian Markison is an operating executive at Avista Capital Partners. Mr. Markison was retained by Avista Capital Partners in 2012. Mr. Markison is a seasoned executive with more than 30 years of operational, marketing, commercial development and sales experience with international pharmaceutical companies. He currently serves as Chairman of the Board and Chief Executive Officer of RVL Pharmaceuticals (Nasdaq: RVLP). Prior to joining Avista, he held the position of President and CEO and member of the Board of Directors of Fougera Pharmaceuticals Inc., a specialty pharmaceutical company in dermatology, prior to its sale to Sandoz, the generics division of Novartis AG. Before leading Fougera, Mr. Markison was Chairman and CEO of King Pharmaceuticals, which he joined as COO in March 2004, and was promoted to President and CEO later that year, and elected Chairman in 2007. Prior to joining King Pharmaceuticals, Mr. Markison held various senior leadership positions at Bristol-Myers Squibb, including President of Oncology, Virology and Oncology Therapeutics Network; President of Neuroscience, Infectious Disease and Dermatology; and Senior Vice President, Operational Excellence and Productivity.
Mr. Markison holds a B.S. degree from Iona College. He currently serves as Chairman of the Board of Lantheus Medical Imaging and is on the Board of Directors of Braeburn Inc., Cosette Pharmaceuticals, and National Spine and Pain Centers. He is also a Director of the College of New Jersey.